Nanoparticle-based immunometabolism approach to mitigate allergic airway inflammation
Tuesday, July 15, 2025
3:38 PM – 3:49 PM EDT
Introduction: Annually 50 million people in the U.S. suffer from allergies with no curative treatments. Allergen-specific immunotherapies represent an antigen (Ag)-specific approach to modulate Th2 dysregulation in allergy, but chronic administration of soluble Ag risks anaphylaxis. Irg1, a gene encoding for cis-aconitate decarboxylase, is upregulated during allergy and produces the immunomodulatory metabolites such as itaconate 1,2. We hypothesize that metabolite-based nanoparticles (NPs) can target the underlying metabolic dysfunction in allergy by modulation of innate and adaptive immune cells.
Learning Objectives:
At the completion of this activity, participants will know
Explain the strengths and weakness of current therapies to treat allergies
Understand the importance of Irg1/itaconate axis in allergic airway inflammation
Evaluate the efficacy of the metabolite-based nanoparticle platform to treat allergic inflammation
